Video

Dr. Traina on Results of the DESTINY-Breast03 Trial in HER2+ Breast Cancer

Tiffany A. Traina, MD, discusses the implications of the phase 3 DESTINY-Breast03 trial in HER2-positive breast cancer.

Tiffany A. Traina, MD, medical oncologist, vice chair, Oncology Care, Department of Medicine, section head, Triple Negative Breast Cancer Clinical Research Program, Memorial Sloan Kettering Cancer Center, discusses the implications of the phase 3 DESTINY-Breast03 trial (NCT03529110) in HER2-positive breast cancer.

The 1:1 randomized trial examined the safety and efficacy of the antibody-drug conjugate, fam-trastuzumab deruxtecan-nxki (Enhertu), vs ado-trastuzumab emtansine (Kaycyla; T-DM1) in the second line and later in patients with HER2-positive metastatic breast cancer, Traina explains. Results demonstrated trastuzumab deruxtecan elicited significantly higher overall response rates (ORRs) compared with T-DM1, Traina adds. Trastuzumab deruxtecan achieved an ORR of 79.7%.

Additionally, the median progression free survival (PFS) was not reached for patients in the trastuzumab deruxtecan group, and the median PFS was 6.8 months for the T-DM1 group, Traina continues. Notably, overall survival data remains immature, but the follow-up presentations are anticipated, Traina concludes

Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing referapatient@mskcc.org, or by calling 833-315-2722.
Related Videos
Bradley C. Carthon, MD, PhD
David C. Fisher, MD
Alan Tan, MD
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss unmet needs and future research directions in ALK-positive and ROS1-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for lorlatinib in ROS1-positive NSCLC after crizotinib and chemotherapy.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for taletrectinib in ROS1-positive advanced non–small cell lung cancer.
Binod Dhakal, MD
Sheldon M. Feldman, MD
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, on progression patterns and subsequent therapies after lorlatinib in ALK-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss preclinical CNS data for the ROS1 inhibitor zidesamtinib.